Genetic variation in STAT4 predicts response to interferon‐α therapy for hepatitis B e antigen‐positive chronic hepatitis B
De‐Ke Jiang, Xiaopan Wu, Ji Qian, Xiao‐Pin Ma, Jingmin Yang, Zhuo Li, Runhua Wang, Li Sun, Fang Liu, Pengyin Zhang, Xilin Zhu, Jia Wu, Kangmei Chen, Carly Conran, S. Lilly Zheng, Daru Lu, Long Yu, Ying Liu, Jianfeng Xu – 24 December 2015 – Interferon (IFN)‐α is a first‐line therapy for chronic hepatitis B (CHB) patients but only initiates a response in a minority of patients. A genetic variant, rs7574865 in STAT4, was recently reported to be associated with risk of developing CHB and hepatitis B virus‐related hepatocellular carcinoma.